CDC - 2012 CRE Toolkit - HAI

CDC - 2012 CRE Toolkit - HAI

Drug-resistant infections threaten patient safety: CDC issues updated guidance to fight deadly carbapenem-resistant Enterobacteriaceae (CRE) across healthcare

CDC issues updated guidance to fight carbapenem-resistant Enterobacteriaceae (CRE) across healthcare

CDC has released updated recommendations that detail how states and healthcare facilities should deal with carbapenem-resistant Enterobacteriaceae (CRE), deadly germs that cause healthcare-associated infections. CRE are resistant to almost all drugs and can contribute to death in 40% of patients who become infected.  Not only are these organisms associated with high mortality rates, but they have the potential to spread quickly.

Combating CRE will require a coordinated effort across healthcare, public health, and industry. To tackle this threat, CDC is releasing its Guidance for Control of Carbapenem-resistant Enterobacteriaceae, a new resource toolkit, which expands on the 2009 recommendations and will continue to evolve as new information becomes available.

To access the new CRE toolkit, visit http://www.cdc.gov/hai/organisms/cre/cre-toolkit/index.html.

To learn more about CRE and resources for patients, clinicians, healthcare facilities, and state health departments, visit CDC’s expanded CRE website.

To learn more about how CRE infections are tracked in the United States, visit http://www.cdc.gov/hai/organisms/cre/TrackingCRE.html.

To view CDC’s latest MMWR on CRE. 

2012 CRE Toolkit - Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE)

Carbapenem-resistant Enterobacteriaceae (CRE) are a serious threat to public health. Infections with CRE are difficult to treat and have been associated with mortality rates as high as 40-50%⁽¹⁾. Due to the movement of patients throughout the healthcare system, if CRE are a problem in one facility, then typically they are a problem in other facilities in the region as well. To help protect patients and prevent transmission, CDC has released a CRE toolkit which expands on the 2009 CDC recommendations and continues to be updated as new information becomes available.

 

Guidance for Control of Carbapenem-resistant Enterobacteriaceae (CRE) - 2012 CRE Toolkit  [PDF - 2.98 MB]

Table of Contents

• Introduction
• Background
• Definitions
• Part 1: Facility-level CRE Prevention
  • Surveillance
  • Facility-level Prevention Strategies
    • Core Measures for All Acute and Long-term Care Facilities.
    • Supplemental Measures for Healthcare Facilities with CRE Transmission
    • Recommendations for Facilities with No or Rare CRE
  • Summary of Prevention Strategies for Acute and Long-term Care Facilities
• Part 2: Regional CRE Prevention: Recommended Strategies for Health Department Implementation
  • Public Health Engagement
  • Regional Surveillance for CRE
  • Regional Prevention Strategies
    • Regions with No CRE Identified
    • Regions with Few CRE Identified
    • Regions Where CRE are Common
  • Appendix A: Previous and Current Clinical and Laboratory Standards Institute Interpretive Criteria for Carbapenems and Enterobacteriaceae
  • Appendix B: General Approach to Carbapenem-resistant Enterobacteriaceae(CRE) Control in Facilities that Rarely or Have Not Identified CRE
  • Appendix C: Example of a Survey for Infection Preventionists
  • Survey of Healthcare Facilities for Carbapenem-resistant Enterobacteriaceae (CRE)
    • Algorithm for Regions with No CRE Identified
    • Algorithm for Regions with Few CRE Identified
    • Algorithm for Regions Where CRE are Common
• Selected References

1. Refers to: Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008;29:1099-106.